🔗 Share this article

Government ministers and leading parliamentarians have raised concerns that the United Kingdom's negotiated accords with Donald Trump are "lacking a solid foundation." This comes after revelations that a much-touted deal on pharmaceutical tariffs, which pledges zero tariffs in exchange for the NHS paying more, lacks any formal legal text beyond vague headline terms outlined by government press releases.

A Deal Without Detail

The arrangement concerning medicines, hailed as a "landmark" achievement, exists as an "broad understanding" without detailed provisions. Critics have noted that the press releases from the UK and US governments present the deal in sharply different terms. The British version emphasizes securing "zero per cent tariffs" as a singular success, while the American announcement dwells on the commitment for the NHS to pay 25% more for new medications.

"We face a genuine possibility that the UK government has promised concessions to raise drug prices in return for little more than a pledge from President Trump," stated David Henig, a trade expert. "It is documented he has a record of not honouring his word."

Broader Instability and a Paused Tech Deal

Worries have been intensified by Washington's move to pause the high-value digital accord, which was previously heralded as "a generational step-change" in the bilateral relationship. The US cited a lack of progress from the UK on reducing other tariffs as the reason for the pause.

Additionally, concessions promised for British farmers as part of an initial accord have not been formally approved by the US, despite a imminent January deadline. "We have been informed that that the US has not yet signed off the reciprocal tariff rate quota," said Tom Bradshaw of the National Farmers' Union.

Uncertainty Among Officials

Privately, ministers have voiced worries that the government's US-UK accords are flimsy and unreliable. One minister was quoted as stating the series of agreements as "resting on shaky ground," while another characterized the situation as the "current reality" in the transatlantic relationship, marked by "increased uncertainty and instability."

Layla Moran, chair of the health select committee, stated: "The only thing more surprising than Trump's temper tantrums is the UK government's optimistic assumption that his administration is a reliable partner. The NHS is not a bargaining chip."

Official Reassurances and Concrete Outcomes

Government figures have sought to reduce the risk of the US reneging on the pharmaceuticals deal. One source noted the US pharmaceutical industry itself had been pushing for the agreement, wanting clarity on imports and pricing, making it more concrete than the paused tech deal.

Officials admit that volatility is part and parcel of dealing with the Trump administration. However, they maintain that the UK has achieved real benefits for businesses, such as reduced duties on automobiles compared to other nations. "The fact we have 25% steel tariffs, which is lower than the rate for the rest of the world, is not flimsy," one official said.

Yet, issues have emerged in enacting the broader trade deal. Promised reciprocal agricultural allowances have failed to be approved, and the commitment to "eliminate duties on UK metals" has not been fulfilled, with tariffs staying at 25%.

Moving forward, the two sides have agreed to resume talks on the paused tech prosperity deal in January, following what were described as "very positive" meetings between UK and US officials in Washington.